Telemedicine once seemed like it was going to revolutionize healthcare.
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Wall Street is forecasting multibagger returns from these two small-cap biotech stocks over the next year.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.
At least one of the pair has a credible shot at finding a home in the market.
Both competitors have promising lead programs, and enough cash, too.
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
The market for weight loss medicines keeps getting hotter and hotter.
In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...
In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...